EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 156 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,712,176 | +13.1% | 58,576 | +2.2% | 0.01% | -12.5% |
| Q3 2022 | $1,514,000 | +63.7% | 57,304 | +175.1% | 0.02% | +77.8% |
| Q2 2022 | $925,000 | -35.3% | 20,829 | -27.9% | 0.01% | +12.5% |
| Q1 2022 | $1,429,000 | -13.1% | 28,874 | -10.6% | 0.01% | -11.1% |
| Q4 2021 | $1,644,000 | +54.2% | 32,295 | +68.9% | 0.01% | +28.6% |
| Q3 2021 | $1,066,000 | +17.1% | 19,118 | -10.0% | 0.01% | +16.7% |
| Q2 2021 | $910,000 | -30.2% | 21,254 | -31.9% | 0.01% | -33.3% |
| Q1 2021 | $1,303,000 | +272.3% | 31,209 | +315.5% | 0.01% | +200.0% |
| Q4 2020 | $350,000 | -57.4% | 7,512 | -61.2% | 0.00% | -70.0% |
| Q3 2020 | $822,000 | +98.1% | 19,340 | +123.6% | 0.01% | +66.7% |
| Q2 2020 | $415,000 | -57.2% | 8,648 | -46.4% | 0.01% | -60.0% |
| Q4 2019 | $970,000 | -28.6% | 16,144 | -32.7% | 0.02% | -28.6% |
| Q3 2019 | $1,358,000 | -28.9% | 24,002 | -30.1% | 0.02% | -38.2% |
| Q2 2019 | $1,911,000 | +42.9% | 34,326 | +29.6% | 0.03% | +54.5% |
| Q1 2019 | $1,337,000 | +72.7% | 26,480 | +103.9% | 0.02% | +29.4% |
| Q3 2017 | $774,000 | – | 12,985 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |